Analysts think CTMX stock price could increase by 331%
Nov 21, 2024, 12:25 PM
25.27%
What does CTMX do
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
7 analysts think CTMX stock price will increase by 331.40%. The current median analyst target is $3.75 compared to a current stock price of $0.87. The lowest analysts target is $3.28 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
